We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
- Authors
Graeser, Monika; Schrading, Simone; Gluz, Oleg; Strobel, Kevin; Herzog, Christopher; Umutlu, Lale; Frydrychowicz, Alex; Rjosk-Dendorfer, Dorothea; Würstlein, Rachel; Culemann, Ralph; Eulenburg, Christine; Adams, Jascha; Nitzsche, Henrik; Prange, Anna; Kümmel, Sherko; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Potenberg, Jochem; von Schumann, Raquel
- Abstract
<bold>Background: </bold>Prediction of histological tumor size by post-neoadjuvant therapy (NAT) ultrasound and magnetic resonance imaging (MRI) was evaluated in different breast cancer subtypes.<bold>Methods: </bold>Imaging was performed after 12-week NAT in patients enrolled into three neoadjuvant WSG ADAPT subtrials. Imaging performance was analyzed for prediction of residual tumor measuring ≤10 mm and summarized using positive (PPV) and negative (NPV) predictive values.<bold>Results: </bold>A total of 248 and 588 patients had MRI and ultrasound, respectively. Tumor size was over- or underestimated by < 10 mm in 4.4% and 21.8% of patients by MRI and in 10.2% and 15.8% by ultrasound. Overall, NPV (proportion of correctly predicted tumor size ≤10 mm) of MRI and ultrasound was 0.92 and 0.83; PPV (correctly predicted tumor size > 10 mm) was 0.52 and 0.61. MRI demonstrated a higher NPV and lower PPV than ultrasound in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive and in HR-/HER2+ tumors. Both methods had a comparable NPV and PPV in HR-/HER2- tumors.<bold>Conclusions: </bold>In HR+/HER2+ and HR-/HER2+ breast cancer, MRI is less likely than ultrasound to underestimate while ultrasound is associated with a lower risk to overestimate tumor size. These findings may help to select the most optimal imaging approach for planning surgery after NAT.<bold>Trial Registration: </bold>Clinicaltrials.gov , NCT01815242 (registered on March 21, 2013), NCT01817452 (registered on March 25, 2013), and NCT01779206 (registered on January 30, 2013).
- Subjects
MAGNETIC resonance imaging; HORMONE receptor positive breast cancer; ULTRASONIC imaging; EPIDERMAL growth factor receptors; BREAST cancer
- Publication
Breast Cancer Research, 2021, Vol 23, Issue 1, p1
- ISSN
1465-5411
- Publication type
journal article
- DOI
10.1186/s13058-021-01413-y